Literature DB >> 26072318

Comparison of COMPUTED TOMOGRAPHY Image Quality Using Intravenous vs. Intraosseous Contrast Administration in Swine.

Jason Cohen1, Luke Duncan1, Wayne Triner2, Jeffrey Rea1, Gary Siskin3, Christopher King2.   

Abstract

BACKGROUND: Vascular access is essential in managing patients with significant injuries. It is required for medications, fluids, blood products, and radiographic contrast administration. Generally, this is accomplished through peripheral intravenous (i.v.) cannulation. In some patients, however, i.v. cannulation may be difficult or impossible. Intraosseous (i.o.) access is an acceptable alternative for many uses during resuscitation. However, adequacy of vascular enhancement with i.o. administration of contrast has not been studied.
OBJECTIVES: This study was performed to assess the efficacy of i.o. administration of contrast agents for enhanced computed tomography (CT) imaging of the chest and abdomen.
METHODS: We carried out a crossover study in mature mini-swine with peripheral i.v. and i.o. access established. Intraosseous access was obtained in the proximal humerus with fluoroscopic confirmation. Each animal underwent two trauma-protocol CT scans successively using the i.v. or i.o. routes of contrast administration. Wash-out between studies was established. The order for route of administration was randomized. Images were evaluated for adequacy of enhancement by two blinded board-certified radiologists.
RESULTS: All images obtained with successful administration of i.o. contrast were judged adequately enhanced, whereas two from the i.v. route were judged to be inadequate by at least one of the radiologists. Two occurrences of failed i.o. needle placement occurred. One animal had complete contrast extravasation resulting in inadequate opacification.
CONCLUSIONS: In this model, injection of contrast through a proximal humerus i.o. resulted in adequate enhancement of trauma-protocol CT images. Our results suggest that i.o. administration of contrast merits further investigation of its potential utility in patients when i.v. access would delay diagnostic evaluation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CT scan; contrast; intraosseous; trauma; vascular access

Mesh:

Substances:

Year:  2015        PMID: 26072318     DOI: 10.1016/j.jemermed.2014.06.036

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  6 in total

1.  Intraarticular extravasation, an unusual complication of computed tomographic angiography performed with intraosseous needle intravenous access.

Authors:  Michael Winkler; Mohamed Issa; Conor Lowry; Yevgen Chornenkyy; Vincent Sorrell
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

Review 2.  The history of bone marrow in orthopaedic surgery (part I trauma): trepanning, bone marrow injection in damage control resuscitation, and bone marrow aspiration to heal fractures.

Authors:  Philippe Hernigou
Journal:  Int Orthop       Date:  2020-02-15       Impact factor: 3.075

3.  CT angiography of the chest and abdomen in an emergency patient via humeral intraosseous access.

Authors:  Nils Markus Budach; Stefan Markus Niehues
Journal:  Emerg Radiol       Date:  2016-08-29

4.  Intraosseous contrast administration for emergency stroke CT.

Authors:  Hermann Krähling; Max Masthoff; Wolfram Schwindt; Christian Paul Stracke; Philipp Schindler
Journal:  Neuroradiology       Date:  2021-01-18       Impact factor: 2.804

5.  The use of intraosseous needles for injection of contrast media for computed tomographic angiography of the thoracic aorta.

Authors:  Michael Winkler; Cynthia Talley; Connor Woodward; Alexander Kingsbury; Frank Appiah; Hossam Elbelasi; Kevin Landwher; Xingzhe Li; Dominik Fleischmann
Journal:  J Cardiovasc Comput Tomogr       Date:  2017-03-16

6.  Intraosseous contrast administration for emergency computed tomography: A case-control study.

Authors:  Philipp Schindler; Anne Helfen; Moritz Wildgruber; Walter Heindel; Christoph Schülke; Max Masthoff
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.